| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |